Pharma company Lupin on Tuesday announced a partnership with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab in several international markets.
As per the agreement, Sandoz will handle the product’s commercialisation in the European Union (excluding Germany), as well as in Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, Lupin said in a statement.
Lupin will be responsible for manufacturing the biosimilar and managing regulatory submissions, the company added.